STAT3 and cervical squamous intraepithelial neoplasia: Strikingly, treatment with tocilizumab, a humanized monoclonal antibody that inhibits IL-6-STAT3 pathway through binding the IL-6 receptor (IL-6R), significantly reduced the viability and proliferation of TNBC cell lines with acute or chronic CIN, but had no effect on cells without CIN induction, or on untransformed breast epithelia cells.